The reduced transcription of fructose bisphosphates 1 (FBP1), a rate-limiting enzyme in gluconeogenesis, mediates disruptions to gluconeogenesis and increased glycolytic activity, causing tumor progression and poor prognosis (Hirata et al., 2016). Here, FBP1 is linked to neoplasm.